AZN | AstraZeneca PLC Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	62.88 - 63.93
52 Week Range	60.47 - 87.68
Beta	0.47
Implied Volatility	28.64%
IV Rank	64.10%
Day's Volume	6,054,022
Average Volume	5,184,885
Shares Outstanding	3,100,600,000
Market Cap	195,957,920,000
Sector	Healthcare
Industry	Drug Manufacturers - General
IPO Date	1993-05-12

Valuation
Profitability
Growth
Health
P/E Ratio	30.53
Forward P/E Ratio	19.63
EPS	2.07
1YR Price Target	79.50
Dividend Yield	1.57%
Dividend Per Share	0.99
Dividend ExDate	2022-08-11
Dividend PayDate	2022-09-12
Employees	89,900
Country	UK
Website	AZN

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.

AZN's peers: AMRN, NVS, GSK, RHHBY, BMY, SNY, MRK, GILD, JNJ, ABBV, LLY, PFE, AMGN, GRFS, NVAX, OGN, SCLX

*Chart delayed

Analyzing fundamentals for AZN we got that it has average fundamentals where Valuation is considered to be fairly valued, Profitability is very poor, Growth is exceptionally good and Health is very weak. For more detailed analysis please see AZN Fundamentals page.

Watching at AZN technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on AZN Technicals page.